Skip to main content
. 2024 May 27;16(5):1259–1270. doi: 10.4240/wjgs.v16.i5.1259

Table 1.

The baseline characteristics of patients before and after propensity-score-matching, n (%)

Factors Before PSM
After PSM
Non-IFD (n = 976)
IFD (n = 97)
χ²
P value
Non-IFD (n = 194)
IFD (n = 97)
    χ²
P value
Gender 6.831 0.009 0.000 1.000
    Female 426 (43.6) 29 (29.9) 58 (29.9) 29 (29.9)
    Male 550 (56.4) 68 (70.1) 136 (70.1) 68 (70.1)
Tumor locations 8.131 0.043 0.000 1.000
    Asending colon 402 (41.2) 51 (52.6) 102 (52.6) 51 (52.6)
    Transverse colon 63 (6.5) 7 (7.2) 14 (7.2) 7 (7.2)
    Descending colon 395 (40.5) 25 (25.8) 50 (25.8) 25 (25.8)
    Sigmoid colon 116 (11.8) 14 (14.4) 28 (14.4) 14 (14.4)
Age (yr) 2.060 0.151 0.063 0.801
    < 65 499 (51.1) 57 (58.7) 111 (57.2) 57 (58.7)
    ≥ 65 477 (48.9) 40 (41.3) 83 (42.8) 40 (41.3)
ASA grade 1.336 0.248 0.248 0.619
    I-II 888 (84.2) 86 (88.7) 168 (86.6) 86 (88.7)
    III-IV 154 (15.8) 11 (11.3) 26 (13.4) 11 (11.3)
CEA 1.212 0.271 1.457 0.227
    < 5 ng/mL 715 (73.3) 66 (68.1) 145 (77.7) 66 (68.1)
    ≥ 5 ng/mL 261 (26.7) 31 (31.9) 49 (22.3) 31 (31.9)
CA19-9 0.039 0.844 1.155 0.282
    < 34 U/mL 852 (87.3) 84 (86.6) 176 (90.8) 84 (86.6)
    ≥ 34 U/mL 124 (22.7) 13 (13.5) 18 (9.2) 13 (13.5)
Hypertension (yes) 316 (32.4) 33 (34.0) 1.109 0.742 63 (32.5) 33 (34.0) 0.070 0.791
DM (yes) 198 (19.9) 18 (18.6) 0.098 0.755 26 (13.4) 18 (18.6) 1.339 0.247
CHD (yes) 98 (10.0) 10 (10.3) 0.007 0.933 10 (5.2) 10 (10.3) 2.685 0.101
Antiplatelet (yes) 89 (9.1) 9 (9.3) 0.003 0.956 10 (5.2) 9 (9.3) 1.802 0.179
Abdominal surgery (yes) 99 (10.1) 12 (12.4) 0.477 0.490 33 (17.1) 12 (12.4) 1.065 0.302

PSM: Propensity score matching; IFD: Intestinal flora disorder; ASA: American society of anesthesiologist; CEA: Carcino embryonic antigen; CA19-9: Carbohydrate antigen 19-9; DM: Diabetes mellitus; CHD: Coronary heart diseases.